ArticleFrontiers in molecular biosciences2025
Comprehensive analysis of phagocytosis regulatory genes in bladder cancer: implications for prognosis and immunotherapy.
Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bladder cancer is a common malignant tumor of the urinary system. Its incidence and mortality rates are on the rise, and the existing treatment methods are difficult to meet the prognostic needs of patients. Phagocytosis plays a crucial role in tumor immune surveillance and the regulation of the tumor microenvironment. Phagocytosis regulatory genes (PRGs) are involved in regulating the immune response against tumor cells, and in-depth research on them in bladder cancer is extremely urgent. Methods: Multi-omics data from the TCGA and GEO databases were integrated, and strict data preprocessing was carried out. A variety of algorithms and analysis techniques, such as Kaplan-Meier analysis, Cox regression analysis, and ConsensusClusterPlus clustering analysis, were used to identify PRGs related to the prognosis of bladder cancer patients, and functional analysis and clustering analysis were conducted in depth. A prognostic model was constructed and verified, and the risk score was calculated. At the same time, the relationships between the model and the tumor microenvironment (TME), immune infiltration, mutation, and drug sensitivity were comprehensively analyzed. Results: It was found that 37 genes had a strong positive correlation with the macrophage score, and 200 PRGs were significantly enriched in immune-related biological processes and pathways. The patients were divided into PRG cluster A and PRG cluster B. Patients in PRG cluster A had a worse survival outcome and were closely related to higher tumor grades, stages, and the infiltration of specific immune cells. A total of 1,696 differentially expressed genes and two phagocytosis-related gene subtypes were identified. The constructed prognostic model showed excellent predictive performance, and the areas under the curves of survival rates at different times were all high in both the training set and the test set. Finally, the drug sensitivity analysis showed that high-risk patients benefited more from immunotherapy and chemotherapy drugs. Conclusion: This study has greatly deepened the understanding of the potential molecular mechanisms of bladder cancer, provided new insights and valuable potential therapeutic targets for the precision treatment of bladder cancer, and is expected to promote the innovation and optimization of bladder cancer treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.